Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth
The new research reports from Fundamental Markets, available for free download at the links above, examine BCE, Inc. (BCE), Nektar Therapeutics (NKTR), Hormel Foods Corporation (HRL), Enanta Pharmaceuticals, Inc. (ENTA), MongoDB, Inc. (MDB), and Regal Beloit Corporation (RBC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. All information in this release was accessed February 13th, 2019. The estimated EPS forecast for the next fiscal year is $2.79 and is expected to report on February 6th, 2020. Hormel Foods' Recent Financial Performance. For the three months ended October 31st, 2018 vs October 31st, 2017, Hormel Foods reported revenue of $2,524.70MM vs $2,492.61MM (up 1.29%) and analysts estimated basic earnings per share $0.49 vs $0.41 (up 19.51%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Hormel Foods reported revenue of $9,545.70MM vs $9,167.52MM (up 4.13%) and analysts estimated basic earnings per share $1.91 vs $1.60 (up 19.38%).